Wall Street's most hated drugmaker is getting annihilated after a bizarre conference call (MNK)

Mallinckrodt Pharmaceuticals missed its Q3 revenue on lower sales of its controversial blockbuster drug, Acthar.
Wall Street didn't like the sales miss. It liked even less that the company had little explanation for the miss on its conference call, and blamed lower sales on an unfulfilled prescription problem.
Hows this for an excuse for a lousy earnings report. Doctors are prescribing our blockbuster drug like crazy, but people just aren't filling prescriptions.The drug in question is cal